Entecavir Hydrate

恩替卡韦

Report date: 2022/12/07 17:05:40
NME

Base Information

Drug NameEntecavir Hydrate
Drug Alias NameEntecavirum乐克ENTECAVIR恩替卡伟恩替卡韦一水化合物 +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHBV DNA Polymerase inhibitorsReverse transcriptase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsFibrosisChronic DiseaseLiver Cirrhosis +[14] 
Global Approved IndicationsHepatitis B, ChronicHepatitis B
Approved Indications in ChinaHepatitis B, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2005/03/29
Country/TerritoryBelgiumCanadaUnited States +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Yinkeruisi Pharmaceutical Technology Co LtdSamsung Medical CenterGuangxi Medical University +[9] 
Inactive CompaniesBristol Myers Squibb SrlcompanyHannover Medical SchoolAucta Pharmaceuticals Inc
Active IndicationsFibrosisLiver CirrhosisGastrointestinal Neoplasms +[9] 
Inactive IndicationsChronic DiseaseLiver FailureLiver Diseases +[5] 

Other Information

ATC CodeJ05AF10
Related LinksWikipediaDrugBankKEGG